Shire Adds To HGT Unit With Lotus Acquisition; Gets Preclinical Rare Disease Treatment
Shire makes a bolt-on acquisition that will complement both its rare disease franchise and its regenerative medicines unit.
Shire makes a bolt-on acquisition that will complement both its rare disease franchise and its regenerative medicines unit.